Media center

We provide ongoing updates on our commercial, clinical and financial progress through regular press releases, presentations and webcasts, which can be accessed through the company’s media center.

Press Releases

Circassia Announces Successful Completion of FDA Pre-submission Meeting for Novel Nitric Oxide Product AirNOvent

Click here to download the full press release Oxford, UK – 4 February 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces its partner,...

Circassia to Acquire US and Chinese Commercialisation Rights to Novel Nitric Oxide Product AirNOvent from AIT Therapeutics Inc.

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014 Click here to download the full press release Oxford, UK – 24 January 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”;...

Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza® from AstraZeneca

Click here to download the full press release Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has...
More press releases

In this section

Press releases

Presentations

Webcasts & audio

Image library

Media contacts